This statistic depicts the share of the U.S. population who suffered from schizophrenia from 1990 to 2019. As of 2019, around 0.47 percent of the population had schizophrenia.

This statistic depicts the share of the U.S. population that were diagnosed with schizophrenia from 1990 to 2019, by gender. As of 2019, around .46 percent of females and .48 percent of males had schizophrenia.

This statistic depicts the share of the population who suffered from schizophrenia worldwide from 1990 to 2019, by gender. As of 2019, around 0.28 percent of females and 0.32 percent of males had schizophrenia.

As of 2021, around 0.3 percent of the global population had schizophrenia. This statistic depicts the share of the population who suffered from schizophrenia worldwide from 1990 to 2021.

Adjustedb'*' regression results evaluating differences in mental health service use among 9,436 home care recipients schizophrenia spectrum and other psychotic disorders (2010–2015), by linguistic group.

Baseline sociodemographic characteristics of 9,436 home care recipients with schizophrenia spectrum and other psychotic disorders (2010–2015), by linguistic group.

OBJECTIVES: To investigate changes in incidence of admissions for schizophrenia and related non-affective psychoses in North Wales. DESIGN: Data from two epidemiologically complete cohorts of patients presenting for the first time to mental health services in North Wales between 1875-1924 and 1994-2010 are used in this study to map the incidence of hospital admissions for schizophrenia and non-affective psychoses. SETTING: The North Wales Asylum Denbigh (archived patient case notes) and the North West Wales District General Hospital psychiatric unit. POPULATION: 3168 patients admitted to the North Wales Asylum Denbigh 1875-1924 and 355 patients admitted to the District General Hospital psychiatric unit 1994-2010. RESULTS: There was an increasing admission incidence for schizophrenia between 1875 and 1900, a higher admission rate in the 1990s for males, followed by a drop in rates of admission for both genders since 2006. Admission incidences switch from parity between the sexes in the historical period to a doubling of the admission rates for men compared to women in the modern period. This admission pattern differs from the admission patterns for affective psychoses or organic disorders. CONCLUSION: There have been changes in the incidence of admissions for schizophrenia in North Wales.

The global antipsychotic drug market is experiencing robust growth, driven by the rising prevalence of mental health disorders like schizophrenia and bipolar disorder, coupled with an aging population. The market size in 2025 is estimated at $20 billion, exhibiting a Compound Annual Growth Rate (CAGR) of 5% from 2025 to 2033. This growth trajectory is fueled by several factors, including increased awareness and diagnosis of mental illnesses, the introduction of novel and effective treatments (particularly within the third-generation antipsychotic drug category), and improved access to healthcare in developing economies. Second-generation antipsychotics currently dominate the market share due to their generally improved side effect profile compared to their first-generation counterparts. However, third-generation antipsychotics are witnessing rapid adoption, signifying a shift in treatment preferences and market dynamics. Despite the promising market outlook, several restraints hinder market expansion. High treatment costs, potential adverse effects associated with certain antipsychotics, and the emergence of generic competition are some of the major challenges. Furthermore, the development of new, more effective, and safer antipsychotics with fewer side effects remains a significant focus for pharmaceutical companies, which could further shape market competition and growth. The market is segmented by drug type (first, second, and third-generation antipsychotics) and application (bipolar I disorder, schizophrenia, schizoaffective disorder, and others). North America and Europe currently represent the largest regional markets due to higher healthcare expenditure and advanced healthcare infrastructure, but Asia Pacific is projected to witness significant growth in the forecast period owing to increasing awareness and improving healthcare access in regions like China and India.

From the fiscal years 2002 to 2022, the age-standardized prevalence of schizophrenia among individuals 10 years and older in Canada constantly increased. The prevalence peaked in 2021-2022, with one percent of the population suffering from schizophrenia. This statistic presents the age-standardized prevalence of schizophrenia among those aged 10 years and older in Canada from 2002 to 2022.

Pooled relative risks of cardiovascular mortality by SMI and cardiovascular outcome.

Overview of disease groups and medicine prevalence in Denmark: Number of patients, prevalence rates per thousands of the total population, prevalence rates per thousand within educational levels, age, and sex, on 1 January 2013.

Antipsychotic Drug Market Outlook

The global antipsychotic drug market size was valued at approximately USD 15 billion in 2023 and is forecasted to reach around USD 22 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.3% during the forecast period. The growth of this market is predominantly driven by the rising prevalence of mental health disorders, advancements in drug development, and increased awareness and diagnosis of psychiatric conditions globally.

One of the primary growth factors for the antipsychotic drug market is the increasing prevalence of mental health disorders such as schizophrenia, bipolar disorder, and major depressive disorder. The World Health Organization (WHO) reports that approximately 1% of the global population is diagnosed with schizophrenia, and bipolar disorder affects around 2.4% of people worldwide. The growing recognition of these mental health disorders fuels the demand for effective treatment options, thereby boosting the market for antipsychotic drugs. Additionally, the stigma around mental health is gradually diminishing, leading to higher diagnosis rates and subsequently an increased demand for these medications.

Another significant growth driver is the continuous innovation and development of new antipsychotic drugs. Pharmaceutical companies are heavily investing in research and development to discover more effective and safer medications. The shift from first-generation antipsychotics to more advanced second- and third-generation antipsychotics offers better therapeutic outcomes with fewer side effects. This innovation not only meets the demands of a growing patient population but also opens up new opportunities for market players to strengthen their product portfolios and market share.

Moreover, the increasing adoption of digital health solutions has transformed the diagnosis and treatment of mental health conditions. Telemedicine and online consultations have made it easier for patients to receive medical advice and prescriptions without the need for physical appointments. This trend has significantly expanded access to mental health care services, especially in remote and underserved areas, thereby driving the growth of the antipsychotic drug market. Furthermore, government initiatives and policies aimed at improving mental health care infrastructure and providing affordable treatment options are also contributing to the market's expansion.

Pimozide is a first-generation antipsychotic that has been traditionally used in the treatment of Tourette's syndrome and other chronic psychotic disorders. Despite the advent of newer antipsychotics, Pimozide remains relevant in specific clinical scenarios due to its efficacy in managing persistent symptoms where other medications may not be as effective. Its mechanism primarily involves dopamine receptor antagonism, which helps in reducing the frequency and intensity of tics and psychotic episodes. However, like many first-generation antipsychotics, Pimozide is associated with a risk of extrapyramidal side effects, requiring careful monitoring and management by healthcare professionals. The ongoing research into optimizing its use and minimizing side effects continues to contribute to its role in the therapeutic landscape.

From a regional perspective, North America dominates the antipsychotic drug market due to the high prevalence of mental health disorders, advanced healthcare infrastructure, and increased healthcare spending. The region's well-established pharmaceutical industry and favorable reimbursement policies further support market growth. Europe follows closely as it benefits from similar factors, including substantial investments in healthcare and strong emphasis on mental health awareness. Asia Pacific is expected to witness the highest growth rate during the forecast period due to the rising incidence of mental health disorders, improving healthcare infrastructure, and increasing healthcare expenditure in emerging economies such as China and India.

Drug Class Analysis

The antipsychotic drug market is segmented into first-generation, second-generation, and third-generation antipsychotics, each with distinct characteristics and therapeutic profiles. First-generation antipsychotics, also known as typical antipsychotics, were the first class of drugs used to treat psychotic disorders. These medications primarily target dopamine receptors but are associated with a high incidence of extrapyramidal side effects (EPS), such as tremor

The global Paliperidone API market is experiencing robust growth, driven by the increasing prevalence of schizophrenia and bipolar disorder, the key therapeutic areas for paliperidone. The market size in 2025 is estimated at $250 million, exhibiting a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033. This growth is fueled by several factors, including the rising geriatric population susceptible to these mental illnesses, increasing awareness and diagnosis rates, and the ongoing development of innovative paliperidone-based formulations. The demand for higher purity grades (≥99%) is expected to outpace that of ≥98% purity, reflecting a trend towards enhanced pharmaceutical quality standards. Furthermore, the tablet formulation segment is projected to dominate the market due to its convenience and ease of administration compared to injection solutions. However, challenges such as stringent regulatory approvals and the potential for generic competition could pose restraints on market expansion in the coming years. Leading players like Suanfarma, Bal Pharma, and Jubilant Pharma are strategically investing in research and development to maintain their market share and cater to evolving patient needs. Geographic expansion, particularly in emerging economies with burgeoning healthcare infrastructure, presents significant growth opportunities. The competitive landscape is marked by a mix of large multinational pharmaceutical companies and smaller specialized API manufacturers. The market's growth trajectory is significantly influenced by pricing strategies, technological advancements in manufacturing processes, and the overall global economic conditions. Future market expansion will heavily depend on the success of new drug delivery systems, expansion into new geographic markets, and the continued development of innovative therapies for schizophrenia and bipolar disorder. The sustained increase in mental health awareness campaigns and government initiatives focused on improved healthcare access are further expected to propel market growth.

BackgroundIn low-income countries, care for people with mental, neurological, and substance use (MNS) disorders is largely absent, especially in rural settings. To increase treatment coverage, integration of mental health services into community and primary healthcare settings is recommended. While this strategy is being rolled out globally, rigorous evaluation of outcomes at each stage of the service delivery pathway from detection to treatment initiation to individual outcomes of care has been missing.Methods and findingsA combination of methods were employed to evaluate the impact of a district mental healthcare plan for depression, psychosis, alcohol use disorder (AUD), and epilepsy as part of the Programme for Improving Mental Health Care (PRIME) in Chitwan District, Nepal. We evaluated 4 components of the service delivery pathway: (1) contact coverage of primary care mental health services, evaluated through a community study (N = 3,482 combined for all waves of community surveys) and through service utilisation data (N = 727); (2) detection of mental illness among participants presenting in primary care facilities, evaluated through a facility study (N = 3,627 combined for all waves of facility surveys); (3) initiation of minimally adequate treatment after diagnosis, evaluated through the same facility study; and (4) treatment outcomes of patients receiving primary-care-based mental health services, evaluated through cohort studies (total N = 449 depression, N = 137; AUD, N = 175; psychosis, N = 95; epilepsy, N = 42). The lack of structured diagnostic assessments (instead of screening tools), the relatively small sample size for some study components, and the uncontrolled nature of the study are among the limitations to be noted. All data collection took place between 15 January 2013 and 15 February 2017. Contact coverage increased 7.5% for AUD (from 0% at baseline), 12.2% for depression (from 0%), 11.7% for epilepsy (from 1.3%), and 50.2% for psychosis (from 3.2%) when using service utilisation data over 12 months; community survey results did not reveal significant changes over time. Health worker detection of depression increased by 15.7% (from 8.9% to 24.6%) 6 months after training, and 10.3% (from 8.9% to 19.2%) 24 months after training; for AUD the increase was 58.9% (from 1.1% to 60.0%) and 11.0% (from 1.1% to 12.1%) for 6 months and 24 months, respectively. Provision of minimally adequate treatment subsequent to diagnosis for depression was 93.9% at 6 months and 66.7% at 24 months; for AUD these values were 95.1% and 75.0%, respectively. Changes in treatment outcomes demonstrated small to moderate effect sizes (9.7-point reduction [d = 0.34] in AUD symptoms, 6.4-point reduction [d = 0.43] in psychosis symptoms, 7.2-point reduction [d = 0.58] in depression symptoms) at 12 months post-treatment.ConclusionsThese combined results make a promising case for the feasibility and impact of community- and primary-care-based services delivered through an integrated district mental healthcare plan in reducing the treatment gap and increasing effective coverage for MNS disorders. While the integrated mental healthcare approach does lead to apparent benefits in most of the outcome metrics, there are still significant areas that require further attention (e.g., no change in community-level contact coverage, attrition in AUD detection rates over time, and relatively low detection rates for depression).

Drugs for Treating Mental Disorders Market Outlook

The global market size for drugs treating mental disorders was valued at $76.2 billion in 2023 and is projected to reach $123.8 billion by 2032, growing at a CAGR of 5.6% during the forecast period. This growth is driven by several factors including increasing awareness of mental health issues, advancements in pharmaceuticals, and rising prevalence of mental disorders globally.

One of the significant growth factors in this market is the increasing awareness and destigmatization of mental health issues. Governments, non-profit organizations, and private entities are increasingly focusing on mental health, running campaigns to promote awareness and understanding. This shift in societal perception is encouraging more individuals to seek treatment, thereby propelling the market growth. Additionally, the ongoing COVID-19 pandemic has heightened mental health awareness, as many individuals face increased stress, anxiety, and depression, further driving demand for mental health drugs.

Technological advancements and innovations in pharmaceuticals are also contributing to market expansion. The advent of next-generation therapeutics, including personalized medicine and combination therapies, is improving treatment outcomes for patients with mental disorders. Research and development activities are at an all-time high, leading to the introduction of novel drugs with better efficacy and fewer side effects. This continuous innovation is expected to maintain a steady growth trajectory for the market over the forecast period.

Another key factor driving market growth is the rising prevalence of mental disorders. According to the World Health Organization (WHO), mental health conditions are on the rise globally, with depression being one of the leading causes of disability. The increasing incidence of mental health conditions such as anxiety, bipolar disorder, and schizophrenia necessitates effective pharmaceutical interventions, thereby bolstering market demand. Moreover, the aging population is more susceptible to mental health issues, further contributing to market growth.

Bipolar Disorder is a significant mental health condition that affects millions of individuals worldwide. Characterized by extreme mood swings, it poses unique challenges for both patients and healthcare providers. The management of bipolar disorder often requires a combination of medications, including mood stabilizers and antipsychotics, to help maintain emotional equilibrium. The increasing awareness and diagnosis of this disorder are driving demand for effective treatments. As research into the underlying mechanisms of bipolar disorder continues, there is hope for the development of novel therapies that can offer better outcomes and fewer side effects for patients. This ongoing research is crucial in addressing the complex nature of bipolar disorder and improving the quality of life for those affected.

From a regional perspective, North America holds the largest market share, attributable to its well-established healthcare infrastructure, high awareness levels, and substantial investment in mental health research. However, the Asia Pacific region is expected to witness the highest growth rate, driven by increasing healthcare expenditure, improving access to mental health services, and growing awareness about mental health issues. The rising prevalence of mental disorders in emerging economies like China and India is also contributing to regional market growth.

Drug Class Analysis

The market for drugs treating mental disorders is segmented by drug class into antidepressants, antipsychotics, anxiolytics, mood stabilizers, stimulants, and others. Antidepressants hold a significant share of the market, driven by the high prevalence of depression worldwide. These drugs are considered the first line of treatment for depression and are also used to treat anxiety disorders, further broadening their application. Continuous research and development in this segment have led to the introduction of more effective and safer antidepressants, contributing to market growth.

Antipsychotics are another crucial segment, primarily used to treat schizophrenia and bipolar disorder. These drugs work by altering the effects of chemicals in the brain and are essential for managing symptoms like hallucinations and delusions. The increasing prevalence of schizophrenia, coupled with growing awareness and diagnosis rates,

The global hallucination and delusion treatment drugs market is expected to reach $XXX million by 2033, with a CAGR of XX% from 2025 to 2033. The market is driven by the increasing prevalence of psychotic disorders such as schizophrenia and bipolar disorder, which are characterized by hallucinations and delusions. Additionally, the geriatric population is more susceptible to psychotic disorders, further contributing to market growth. Furthermore, technological advancements in drug development and the introduction of novel therapeutics are expected to fuel market expansion. Key players in the market include Johnson & Johnson, Novartis, Pfizer, and Eli Lilly. North America dominates the market, followed by Europe and Asia Pacific. The market is segmented by application (schizophrenia, bipolar disorder, others) and type (atypical antipsychotics, typical antipsychotics). Atypical antipsychotics are expected to hold a significant market share due to their improved efficacy and tolerability compared to typical antipsychotics. The increasing availability of generic drugs is expected to restrain market growth to some extent.

Subdivided by causes of death.*Number of deaths.**All diseases and medical conditions.

Psychiatric Medications Market Outlook

The global psychiatric medications market size was valued at approximately USD 50 billion in 2023 and is projected to grow to around USD 80 billion by 2032, expanding at a compound annual growth rate (CAGR) of 5.2% during the forecast period. The market is witnessing robust growth, driven by an increasing prevalence of mental health disorders, rising awareness about mental health, and advancements in pharmaceutical treatments. Factors such as the rising geriatric population, growing stress-related conditions, and the increasing diagnosis rates of psychiatric disorders are significantly contributing to the market's expansion.

One of the primary growth factors in the psychiatric medications market is the rising prevalence of mental health disorders globally. Conditions such as depression, anxiety, schizophrenia, and bipolar disorder are becoming more common, driven by lifestyle changes, societal pressures, and increasing awareness and diagnosis. According to the World Health Organization (WHO), depression is projected to become the second leading cause of disability worldwide, further emphasizing the need for effective psychiatric medications. Additionally, the stigma around mental health is slowly diminishing, encouraging more people to seek treatment and boosting market growth.

Advancements in pharmaceutical research and development are another critical factor propelling the growth of the psychiatric medications market. The continuous development of new medications with improved efficacy and reduced side effects is enhancing patient compliance and treatment outcomes. Innovations such as novel drug delivery systems, combination therapies, and personalized medicine tailored to individual genetic profiles are also contributing to market expansion. These advancements not only offer better therapeutic options but also attract significant investments from both public and private sectors.

Government initiatives and funding aimed at improving mental health care are playing a crucial role in market growth. Many countries are recognizing the importance of mental health and are implementing policies to improve access to psychiatric care and medications. For instance, various national and international health organizations are launching campaigns and programs to raise awareness about mental health issues and the availability of treatments. Such initiatives are expected to drive the demand for psychiatric medications further.

The regional outlook for the psychiatric medications market indicates a significant growth potential across various geographical regions. North America holds a substantial market share due to high healthcare expenditure, advanced healthcare infrastructure, and increased awareness of mental health issues. Europe also represents a large market, driven by favorable government policies and a well-established healthcare system. The Asia Pacific region is expected to witness the highest growth rate, attributed to the increasing prevalence of mental health disorders, rising healthcare expenditure, and growing awareness about mental health. Developing regions such as Latin America and the Middle East & Africa are also projected to offer lucrative opportunities due to improving healthcare infrastructure and rising mental health awareness.

Drug Class Analysis

The psychiatric medications market is segmented into various drug classes, including antidepressants, antipsychotics, mood stabilizers, anxiolytics, stimulants, and others. Antidepressants hold a significant share of the market due to their widespread use in treating depression, a condition affecting millions of people worldwide. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are among the most commonly prescribed antidepressants. These medications help alleviate symptoms of depression by balancing neurotransmitters in the brain, thereby improving mood and emotional stability.

Antipsychotics are another major segment within the psychiatric medications market, primarily used to treat schizophrenia and other psychotic disorders. These medications help manage symptoms such as hallucinations, delusions, and disorganized thinking. Second-generation antipsychotics, also known as atypical antipsychotics, are often preferred due to their lower risk of side effects compared to first-generation antipsychotics. The development of long-acting injectable antipsychotics has also improved patient compliance and treatment outcomes, contributing to the growth of this segment.

Mood

N-Back indices Pearson Correlations.

In 2023, about 169.5 per 10 thousand individuals in Italy were treated for some kind of mental health disorder. This statistic breaks down this figure by diagnosis. According to the data, the most common mental health disorders treated among the Italian population were depression, schizophrenia, and psychoses. The diagnosis-related groups registering the lowest prevalence were dementia, organic mental disorders, alcoholism, and drug addiction. Mental health and gender Gender plays a relevant role in mental health, in the probability specific mental disorders will occur and in the decision to seek help. Women, for example, are more prone to suffer from depression, while men from schizophrenia and psychoses. In 2021, roughly 43.5 women per 10,000 inhabitants were suffering from depression, while this figure was 25.6 per 10,000 men. During the same period, the highest rate of patients treated in mental health wards was among women. Mental health ward patients The number of people that are treated in mental health wards in Italy varies greatly across the country. In 2021, the region with the highest number of mental health ward patients was Lombardy, with over 130 thousand, followed by the regions of Campania and Emilia Romagna, with 76 thousand and almost 68 thousand patients, respectively. During the same period, most of the patients treated in mental health wards in Italy were aged between 45 and 64 years.